PHGE
$5.23
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
Intraday
Recent News
BiomX announces $3M private placement
BiomX (PHGE) entered into definitive agreements in connection with a private investment in public equity financing for expected gross proceeds of approximately $3M, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. In the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of $1,000 per share, together with warrants w
All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy
BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the
Top Midday Decliners
Meihua International Medical Technologies (MHUA) shares plunged 43% after the company reported late
BiomX Inc (PHGE) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
BiomX Inc (PHGE) progresses in clinical trials for BX004 and BX011, despite facing financial constraints and a temporary FDA hold on US trials.